menu
    • menu
    PHARMACOMPASS
    PHARMACOMPASS

    Grow Your Pharma Business Digitally
    X
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Celgene Corp`s Reblozyl® (luspatercept-aamt) Receives Suppl Approval in US

    FDA

    Ahead of likely approval, ICER finds Geron’s imetelstat at $250,000 annually

    ENDPTS

    EC Expands Approval of BMS Reblozyl for LR-MDS

    BUSINESSWIRE

    EC expands Reblozyl’s approval for treatment of myelodysplastic syndromes

    INDIANPHARMAPOST

    Bristol Myers Squibb Receives Positive CHMP Opinion for Reblozyl

    BUSINESSWIRE

    BMS Presents Efficacy and Safety Analysis of the Phase 3 Trial of Reblozyl

    BUSINESSWIRE

    FDA Approval Insights: First-Line Luspatercept for Anemia in Lower-Risk MDS

    ONCLIVE

    Roche`s SMA drug Evrysdi gets EU okay for pre-symptomatic babies

    GLOBENEWSWIRE

    Bristol Myers Squibb has FDA approval for Reblozyl for anaemia

    PRESS RELEASE

    U.S. FDA Approves BMS’s Reblozyl as First-Line Treatment of Anemia in Adults MDS

    BUSINESSWIRE

    Bristol Myers details PhIII win in first-line test of Reblozyl

    ENDPTS

    ASCO: BMS` $4B plan for Reblozyl takes shape—with one caveat

    FIERCE PHARMA

    BMS to Present Results at ASCO and EHA from Phase 3 COMMANDS Study of Reblozyl

    BUSINESSWIRE

    FDA Accepts for Priority Review sBLA and EMA Validates Application for Reblozyl

    PRESS RELEASE

    Bristol Myers Squibb’s TRANSCEND FL and TRANSCEND NHL 001 Studies of Breyanzi

    BUSINESSWIRE

    U.S. FDA Accepts for Priority Review Sbla & EMA Validates for Reblozyl

    BUSINESSWIRE

    Bristol Myers Squibb bags third indication for Reblozyl in EU

    BUSINESSWIRE

    Bristol Myers Squibb Receives Positive CHMP Opinion for Reblozyl for Adult

    BUSINESSWIRE

    New therapy for anaemic myelodysplastic cancer patients

    EUROPEANPHARMACEUTICALREVIEW

    BMS scores a topline treat in Reblozyl phase 3 study

    FIERCEPHARMA

    Celgene Corp`s Reblozyl® (luspatercept-aamt) Receives Approval in US

    FDA

    BMS Withdraws sBLA for Reblozyl for NTD Beta Thalassemia

    BUSINESSWIRE

    What To Expect From Bristol Myers Squibb Stock After Q1 Results?

    FORBES

    BMS Announces New PDUFA Goal Date for Reblozyl sBLA

    BUSINESSWIRE

    BMS and Acceleron Present First Results from Phase 2 BEYOND Study of Reblozyl

    BUSINESSWIRE

    Luspatercept is effective and well tolerated in patients with beta-thalassemia

    PRNEWSWIRE

    Luspatercept is Efficacious and Well-Tolerated in Patients with ?-Thalassemia

    PRNEWSWIRE

    BMS and Acceleron Present First Results from Phase 2 BEYOND Study of Reblozyl

    BUSINESSWIRE

    Luspatercept is effective and well tolerated in patients with beta-thalassemia

    PRNEWSWIRE

    Luspatercept is Efficacious and Well-Tolerated in Patients with ?-Thalassemia

    PRNEWSWIRE

    Health Canada Approves REBLOZYL® (luspatercept), New Class

    BIOSPACE

    Health Canada Approves REBLOZYL® (luspatercept), New Class of Treatment

    BUSINESSWIRE

    Acceleron Announces REBLOZYL® (luspatercept-aamt) Virtual Presentations

    BUSINESSWIRE

    Health Canada Approves REBLOZYL

    BIOSPACE

    Health Canada Approves REBLOZYL® (luspatercept)

    BUSINESSWIRE

    Celgene Europe BV Generic Reblozyl (Luspatercept) Receives Approval in Europe

    EMA

    EC clears new class of anaemia therapy

    PHARMATIMES

    European Commission Approves Reblozyl (luspatercept)

    BUSINESSWIRE

    Acceleron Announces Presentations on REBLOZYL luspatercept-aamt at the 2020 ASCO

    BUSINESSWIRE

    Reblozyl (luspatercept) Receives +ve CHMP Opinion for the Treatment of Adults

    BUSINESSWIRE

    BMY`s, Acceleron rack up second OK for Reblozyl, onto blockbuster status

    PRESS RELEASE

    Celgene`s Reblozyl (luspatercept-aamt) Receives Supplemental Approval in US

    FDA

    New England Journal of Medicine Publishes Results from Pivotal Phase 3

    BUSINESSWIRE

    NEJM Publishes Results from Pivotal Phase 3 BELIEVE Trial of Reblozyl

    PRESS RELEASE

    Meeting of the Oncologic Drugs Advisory Committee Meeting Announcement

    FDA

    Bristol and Acceleron Provide Update on FDA Advisory Committee for Reblozyl

    BUSINESS WIRE

    Celgene`s Reblozyl faces FDA committee for myelodysplastic syndromes

    FIERCE PHARMA

    Can Biohaven challenge the Allergan/AbbVie goliath in migraine?

    FIERCE PHARMA

    Celgene`s Reblozyl (luspatercept-aamt) Receives Supplemental Approval in US

    FDA

    FDA approves first therapy to treat patients with rare blood disorder

    PR NEWSWIRE

    Another failed midstage asset for Acceleron sees shares fall

    FIERCE BIOTECH

    Celgene wins approval for drug key to Bristol buyout

    BIOPHARMADIVE

    Bristol-Myers` Celgene buy just chalked up another point in its favor

    FIERCE PHARMA

    Celgene gains FDA review for blockbuster hopeful

    FIERCE BIOTECH

    Celgene wraps up EU, U.S. filings for anemia drug luspatercept

    FIERCE BIOTECH

    Celgene Submits Luspatercept MAA for MDS and Beta-Thalassemia to EMA

    BUSINESSWIRE

    Celgene, Acceleron submit FDA application for billed blockbuster luspatercept

    ENDPTS

    Celgene Corporation & Acceleron Announce Submission of Luspatercept BLA

    BUSINESSWIRE

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.